Calcitriol

Chemical name

(1альфа,3бета,5Z,7E)-9,10-Се��охолеста-5,7,10-(19)-триен -1,3,25-триол

Gross

C27-H44-O3

Characteristics

The white crystalline powder. Rat in the organic solvent, relatively soluble in water.

Of drugs

The drugs-D-vitaminopodobnoe. Does calcium absorption in the gut, regulates bone mineralization, stimulates osteoblasta.

Indications

Osteodistrofia kidney genesis (in patients with renal insufficiency, including at a dialysis), menopausal osteoporosis, posleoperazionny and idiopathic gipoparatireoz, psevdogipoparatireoz, psevdodefitsitny Vitamin-d-zawisimy rickets, congenital витамин-D-резистентны�� rickets (fosfat-diabet).

Contraindications

Hypersensitivity, gipercalziemia, pregnancy, breast-feeding (should abandon breastfeeding).

Side-Effects

Gipercalziemia, anorexia, headache, vomiting, gastralgia, intestinal kolica, calzinoz soft tissues, the activity of liver transaminaz, constipation, weight, the sensitivity disorder, fever, thirst, poliuria, dehydration, dizziness, lethargy, stunting, urinary tract infections.

Patient interaction

Tiazidnye dioretiki increase the risk gipercalziemii. Adrenal Activation reduce calcium absorption in the gut. Amphetamine mikrosomalnogo oxidation (phenytoin, and phenobarbital) and holestiramin reduce suction and reducyruut concentration in the serum. Incompatible with vitamin D and its derivatives. Increases toxicity of cardiac glycosides. While magnisoderjath drugs increases the risk of gipermagniemii.

Precautions

The calcium and creatinine should be determined through four weeks, 3 and 6 months after the start of treatment, and then at intervals of six months. The daily dose of 5 g and above should be appointed with great caution (clinical examination, determination of the level of calcium, phosphorus and activity of alkaline phosphatase in the blood to be held twice a week). To apply caution in children.

Dosing and Administration

Inside, the optimal daily dose of eight, depending on the level of calziemii. Initial daily intake of 0.25 g. If clinical indicators improved in the next two to four weeks of treatment, the daily dose increased by 0.25 µ g-medium (0.5-1 g / day) and above. When menopausal osteoporosis by 0.25 µ g twice a day. In renal osteodystrophies initial daily dose of 0.25 µ g, patients with normal or slightly reduced level of calcium whey is 0.25 micrograms a day. In gipoparatireoze and rahite initial dose of 0.25 µ g / day (morning). In fosfat-diabete shown additional appointment containing products. For children 0.01-0.1 µ g / kg

Directory → Metaboliki → Corrector metabolism of bone and cartilage tissue → Calcitriol